Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.

[1]  S. Morris,et al.  Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy. , 2015, American journal of physiology. Renal physiology.

[2]  T. Schall,et al.  The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. , 2015, The lancet. Diabetes & endocrinology.

[3]  J. Vacher,et al.  Macrophage-derived Tumor Necrosis Factor-α mediates diabetic renal injury , 2015, Kidney international.

[4]  S. Morris,et al.  Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation. , 2014, American journal of physiology. Renal physiology.

[5]  T. Cooper,et al.  Macrophages directly mediate diabetic renal injury. , 2013, American journal of physiology. Renal physiology.

[6]  S. Morris,et al.  Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism , 2013, Kidney international.

[7]  M. Okusa,et al.  Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. , 2011, American journal of physiology. Renal physiology.

[8]  S. Morris,et al.  Arginase-2 Mediates Diabetic Renal Injury , 2011, Diabetes.

[9]  P. Mattei,et al.  An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. , 2011, Kidney international.

[10]  Liping Huang,et al.  Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. , 2011, Kidney international.

[11]  Hyoung-Kyu kim,et al.  CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. , 2010, Kidney international.

[12]  C. Alpers,et al.  Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[13]  G. Camussi,et al.  Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes , 2009, Diabetes.

[14]  Yuichiro Yamada,et al.  Reduction of renal superoxide dismutase in progressive diabetic nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.

[15]  J. Navarro-González,et al.  Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. , 2009, Cytokine & growth factor reviews.

[16]  T. Yoo,et al.  MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. , 2008, American journal of physiology. Renal physiology.

[17]  S. Shankland,et al.  Proteinuria in diabetic kidney disease: a mechanistic viewpoint. , 2008, Kidney international.

[18]  P. Dentelli,et al.  The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. , 2007, The American journal of pathology.

[19]  M. Mack,et al.  Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. , 2007, The Journal of clinical investigation.

[20]  M. Nakajima,et al.  Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome. , 2006, The American journal of pathology.

[21]  R. Atkins,et al.  Macrophage accumulation in human progressive diabetic nephropathy , 2006, Nephrology.

[22]  G. Camussi,et al.  The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. , 2006, Kidney international.

[23]  E. Pamer,et al.  Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2 , 2006, Nature Immunology.

[24]  Y. Tomino,et al.  Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  W. Kuziel,et al.  Chemokine receptor CCR2 involvement in skeletal muscle regeneration , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  R. Kalluri,et al.  Induction of B7-1 in podocytes is associated with nephrotic syndrome. , 2004, The Journal of clinical investigation.

[27]  H. Siragy,et al.  Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. , 2003, Kidney international.

[28]  L. Holzman,et al.  Two gene fragments that direct podocyte-specific expression in transgenic mice. , 2002, Journal of the American Society of Nephrology : JASN.

[29]  R. S. Tepper,et al.  Induction of MCP-1 Expression in Airway Epithelial Cells: Role of CCR2 Receptor in Airway Epithelial Injury , 2002, Journal of Clinical Immunology.

[30]  D. Laskin,et al.  Role of CCR2 in macrophage migration into the liver during acetaminophen‐induced hepatotoxicity in the mouse , 2002, Hepatology.

[31]  W. Rostène,et al.  Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain , 2002, Journal of neurochemistry.

[32]  M. Burdick,et al.  Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. , 2001, The Journal of clinical investigation.

[33]  R. Atkins,et al.  The role of macrophages in glomerulonephritis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  M. Steffes,et al.  Glomerular cell number in normal subjects and in type 1 diabetic patients. , 2001, Kidney international.

[35]  K. Ohshiro,et al.  Phenotypic modulation of parietal epithelial cells of Bowman's capsule in culture , 2001, Cell and Tissue Research.

[36]  H. Weiner,et al.  Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the Cc Chemokine Receptor (Ccr2) , 2000, The Journal of experimental medicine.

[37]  H. Gröne,et al.  Expression of CCR2 by endothelial cells : implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  N. Maeda,et al.  Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. , 1999, Atherosclerosis.

[39]  M. Cooper,et al.  Pathogenesis, prevention, and treatment of diabetic nephropathy , 1998, The Lancet.

[40]  H. Makino,et al.  Increased expression of selectins in kidneys of patients with diabetic nephropathy , 1998, Diabetologia.

[41]  T. Meyer,et al.  Podocyte loss and progressive glomerular injury in type II diabetes. , 1997, The Journal of clinical investigation.

[42]  B. Rovin,et al.  Monocyte chemoattractant protein-1 levels in patients with glomerular disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  K. Yoshinaga,et al.  The role of macrophages in diabetic glomerulosclerosis. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  S. Satchell,et al.  Diabetic nephropathy. , 2012, Clinical medicine.

[45]  T. Yoo,et al.  The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions , 2011, Apoptosis.

[46]  T. Moore,et al.  CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. , 2005, The American journal of pathology.

[47]  B. Moore,et al.  Expression and functional implications of CCR2 expression on murine alveolar epithelial cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[48]  北川 清樹.  Blockade of CCR2 ameliorates progressive fibrosis in kidney , 2004 .